SCHEMBL8049334

SCHEMBL8049334

CCOC(=O)[C@H]1Cc2ccccc2[C@H]1O

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
ATM Q13315 1/20 0.41
OPRM1 P35372 1/20 0.40
KDM4E B2RXH2 2/20 0.40
NR1D1 P20393 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8037835 1.00 TSHR (0.45) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL8037300 0.85 TSHR (0.43) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL7708841 0.85 TSHR (0.43) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL8048116 0.85 TSHR (0.43) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL4815395 0.84 NR1D1 (0.48) TSHRMAPTPKMATMKDM4E
SCHEMBL14193309 0.84 NR1D1 (0.48) TSHRMAPTPKMATMKDM4E
SCHEMBL8269018 0.84 MAPT (0.41) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL8269016 0.84 MAPT (0.41) TSHRCYP1A2CYP2C19MAPTPKM
SCHEMBL22992354 0.83 CYP1A2 (0.42) TSHRCYP1A2CYP2C19MAPTOPRM1
SCHEMBL8037590 0.81 MEN1 (0.40) TSHRCYP1A2CYP2C19MAPTOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
WO-2016025681-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-18 WO disclosed
EP-0991772-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS Biocatalytics, Inc. (US) 2000-04-12 EP disclosed
US-5942644-A Precursors for the production of chiral vicinal aminoalcohols BIOCATALYTICS, INC. (US) 1999-08-24 US disclosed
WO-1998054350-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS BIOCATALYTICS, INC. (US) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CD81, ICAM1 TSHR 4775/4885CYP1A2 4206/4885CYP2C19 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.